| NCT04208035 |
Hepatitis C Elimination in the Netherlands |
https://ClinicalTrials.gov/show/NCT04208035 |
Recruiting |
Radboud University |
2021-01-01 |
| NCT03366610 |
Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens |
https://ClinicalTrials.gov/show/NCT03366610 |
Completed |
Bristol-Myers Squibb |
2019-04-30 |
| NCT03343925 |
Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings |
https://ClinicalTrials.gov/show/NCT03343925 |
Recruiting |
Kirby Institute |
2021-07-01 |
| NCT03313154 |
Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related |
https://ClinicalTrials.gov/show/NCT03313154 |
Completed |
Azienda Ospedaliero Universitaria di Cagliari |
2018-07-31 |
| NCT03303599 |
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 |
https://ClinicalTrials.gov/show/NCT03303599 |
Completed |
AbbVie |
2020-01-24 |
| NCT03248622 |
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection |
https://ClinicalTrials.gov/show/NCT03248622 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-05-28 |
| NCT03200379 |
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan |
https://ClinicalTrials.gov/show/NCT03200379 |
Recruiting |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2037-06-15 |
| NCT03181074 |
Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults |
https://ClinicalTrials.gov/show/NCT03181074 |
Completed |
Bristol-Myers Squibb |
2019-08-19 |
| NCT03149289 |
Hepatitis C Virus Infection in Patients With Hemoglobinopathies |
https://ClinicalTrials.gov/show/NCT03149289 |
Completed |
Società Italiana Talassemie ed Emoglobinopatie |
2016-03-01 |
| NCT03144440 |
Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel |
https://ClinicalTrials.gov/show/NCT03144440 |
Active, not recruiting |
Carmel Medical Center |
2020-01-01 |
| NCT03088917 |
‘Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat’ |
https://ClinicalTrials.gov/show/NCT03088917 |
Completed |
Radboud University |
2019-12-01 |
| NCT03063723 |
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs |
https://ClinicalTrials.gov/show/NCT03063723 |
Completed |
Third Affiliated Hospital, Sun Yat-Sen University |
2016-12-01 |
| NCT03053180 |
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation |
https://ClinicalTrials.gov/show/NCT03053180 |
Completed |
AbbVie |
2017-12-18 |
| NCT03038763 |
Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers |
https://ClinicalTrials.gov/show/NCT03038763 |
Completed |
University of Pennsylvania |
2019-06-30 |
| NCT03002818 |
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) |
https://ClinicalTrials.gov/show/NCT03002818 |
Completed |
AbbVie |
2018-04-25 |
| NCT02945228 |
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2 |
https://ClinicalTrials.gov/show/NCT02945228 |
Completed |
AbbVie |
2019-07-26 |
| NCT02851069 |
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia |
https://ClinicalTrials.gov/show/NCT02851069 |
Completed |
AbbVie |
2018-08-30 |
| NCT02850289 |
APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin |
https://ClinicalTrials.gov/show/NCT02850289 |
Completed |
Hoffmann-La Roche |
2008-10-31 |
| NCT02817594 |
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02817594 |
Completed |
AbbVie |
2018-03-07 |
| NCT02807402 |
Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania |
https://ClinicalTrials.gov/show/NCT02807402 |
Completed |
AbbVie |
2017-08-04 |
| NCT02803138 |
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02803138 |
Completed |
AbbVie |
2018-10-21 |
| NCT02798315 |
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study |
https://ClinicalTrials.gov/show/NCT02798315 |
Completed |
AbbVie |
2017-06-12 |
| NCT02788682 |
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy |
https://ClinicalTrials.gov/show/NCT02788682 |
Completed |
Cairo University |
2015-07-31 |
| NCT02785835 |
Hepatocellular Carcinoma in HIV-infected Patients |
https://ClinicalTrials.gov/show/NCT02785835 |
Recruiting |
Hospital Universitario de Valme |
2016-12-31 |
| NCT02783976 |
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice |
https://ClinicalTrials.gov/show/NCT02783976 |
Completed |
Gilead Sciences |
2018-06-20 |
| NCT02758509 |
Impact of Antiviral Therapy on Gastroesophageal Varices. |
https://ClinicalTrials.gov/show/NCT02758509 |
Completed |
Parc de Salut Mar |
2017-06-15 |
| NCT02726022 |
A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels |
https://ClinicalTrials.gov/show/NCT02726022 |
Completed |
Hoffmann-La Roche |
2011-07-31 |
| NCT02725866 |
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02725866 |
Completed |
AbbVie |
2017-10-31 |
| NCT02714712 |
SR-BI and Antiviral Treatment Response in HCV |
https://ClinicalTrials.gov/show/NCT02714712 |
Completed |
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation |
2016-07-31 |
| NCT02669940 |
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation |
https://ClinicalTrials.gov/show/NCT02669940 |
Completed |
AbbVie |
2017-07-04 |
| NCT02640547 |
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02640547 |
Completed |
AbbVie |
2017-03-29 |
| NCT02636608 |
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary |
https://ClinicalTrials.gov/show/NCT02636608 |
Completed |
AbbVie |
2018-05-23 |
| NCT02629172 |
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 |
https://ClinicalTrials.gov/show/NCT02629172 |
Completed |
AbbVie |
2019-02-28 |
| NCT02618928 |
The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France |
https://ClinicalTrials.gov/show/NCT02618928 |
Completed |
AbbVie |
2018-03-29 |
| NCT02615145 |
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) |
https://ClinicalTrials.gov/show/NCT02615145 |
Completed |
AbbVie |
2018-03-26 |
| NCT02601820 |
The Patient-Reported Outcomes Project of HCV-TARGET |
https://ClinicalTrials.gov/show/NCT02601820 |
Completed |
University of North Carolina, Chapel Hill |
2018-07-31 |
| NCT02592057 |
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India |
https://ClinicalTrials.gov/show/NCT02592057 |
Completed |
Gilead Sciences |
2017-11-30 |
| NCT02583243 |
Project BEST: Buprenorphine Entry Into Substance Abuse Treatment |
https://ClinicalTrials.gov/show/NCT02583243 |
Completed |
Yale University |
2008-08-31 |
| NCT02582671 |
The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland |
https://ClinicalTrials.gov/show/NCT02582671 |
Completed |
AbbVie |
2017-11-29 |
| NCT02582658 |
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) |
https://ClinicalTrials.gov/show/NCT02582658 |
Completed |
AbbVie |
2017-01-12 |
| NCT02581189 |
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada |
https://ClinicalTrials.gov/show/NCT02581189 |
Completed |
AbbVie |
2017-12-20 |
| NCT02557646 |
An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02557646 |
Completed |
Hoffmann-La Roche |
2014-03-31 |
| NCT02556307 |
A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients |
https://ClinicalTrials.gov/show/NCT02556307 |
Completed |
Hoffmann-La Roche |
2014-07-31 |
| NCT02545335 |
Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02545335 |
Active, not recruiting |
Medical University of Graz |
2020-12-31 |
| NCT02531269 |
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period |
https://ClinicalTrials.gov/show/NCT02531269 |
Completed |
Bristol-Myers Squibb |
2016-02-29 |
| NCT02528461 |
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02528461 |
Completed |
University of Aarhus |
2019-01-31 |
| NCT02526641 |
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02526641 |
Active, not recruiting |
University of Aarhus |
2019-03-31 |
| NCT02508090 |
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin |
https://ClinicalTrials.gov/show/NCT02508090 |
Completed |
Hoffmann-La Roche |
2017-01-13 |
| NCT02452814 |
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection |
https://ClinicalTrials.gov/show/NCT02452814 |
Completed |
Hoffmann-La Roche |
2017-05-03 |
| NCT02439918 |
Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa |
https://ClinicalTrials.gov/show/NCT02439918 |
Completed |
Université de Sherbrooke |
2012-08-31 |
| NCT02333292 |
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions |
https://ClinicalTrials.gov/show/NCT02333292 |
Recruiting |
Valme University Hospital |
2020-11-30 |
| NCT02106156 |
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) |
https://ClinicalTrials.gov/show/NCT02106156 |
Completed |
Hoffmann-La Roche |
2013-09-30 |
| NCT02068963 |
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing |
https://ClinicalTrials.gov/show/NCT02068963 |
Completed |
Hologic, Inc. |
2015-04-30 |
| NCT02065999 |
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients |
https://ClinicalTrials.gov/show/NCT02065999 |
Recruiting |
Kirby Institute |
2022-04-30 |
| NCT01310205 |
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV |
https://ClinicalTrials.gov/show/NCT01310205 |
Completed |
SciClone Pharmaceuticals |
2012-03-31 |
| NCT01272479 |
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01272479 |
Completed |
Istanbul University |
2010-03-31 |
| NCT02057003 |
Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients |
https://ClinicalTrials.gov/show/NCT02057003 |
Recruiting |
Valme University Hospital |
2020-12-31 |
| NCT04202081 |
Voices From the Black Community: Hepatitis C Research Participation |
https://ClinicalTrials.gov/show/NCT04202081 |
Completed |
University of North Carolina, Chapel Hill |
2020-05-15 |
| NCT02951364 |
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea |
https://ClinicalTrials.gov/show/NCT02951364 |
Recruiting |
Gilead Sciences |
2021-10-31 |
| NCT02011932 |
Prospective Observational Study of Disease Progression in Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02011932 |
Active, not recruiting |
Beijing YouAn Hospital |
2011-06-30 |
| NCT02006823 |
Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT02006823 |
Completed |
Duke University |
2014-07-31 |
| NCT01980290 |
Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01980290 |
Completed |
Janssen Pharmaceutica N.V., Belgium |
2015-02-28 |
| NCT01945008 |
Observational Study in HCV Chronic Infection |
https://ClinicalTrials.gov/show/NCT01945008 |
Completed |
Istituto Superiore di Sanità |
2015-11-30 |
| NCT01884402 |
Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 |
https://ClinicalTrials.gov/show/NCT01884402 |
Completed |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
2014-05-31 |
| NCT01850745 |
Multidisciplinary Support Program in Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01850745 |
Completed |
Parc de Salut Mar |
2009-01-31 |
| NCT01771653 |
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection |
https://ClinicalTrials.gov/show/NCT01771653 |
Completed |
Southern Illinois University |
2015-07-31 |
| NCT01750216 |
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 |
https://ClinicalTrials.gov/show/NCT01750216 |
Completed |
Hoffmann-La Roche |
2015-01-31 |
| NCT01711164 |
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis |
https://ClinicalTrials.gov/show/NCT01711164 |
Completed |
University Health Network, Toronto |
2016-05-31 |
| NCT01705717 |
A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01705717 |
Completed |
Hoffmann-La Roche |
2012-05-01 |
| NCT01679834 |
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01679834 |
Completed |
Hoffmann-La Roche |
2017-07-14 |
| NCT01671046 |
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection |
https://ClinicalTrials.gov/show/NCT01671046 |
Completed |
Hoffmann-La Roche |
2015-12-31 |
| NCT01667081 |
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) |
https://ClinicalTrials.gov/show/NCT01667081 |
Enrolling by invitation |
Merck Sharp & Dohme Corp. |
2021-05-24 |
| NCT01659567 |
A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C |
https://ClinicalTrials.gov/show/NCT01659567 |
Completed |
Hoffmann-La Roche |
2015-10-20 |
| NCT01641094 |
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms |
https://ClinicalTrials.gov/show/NCT01641094 |
Completed |
Foundation for Liver Research |
2014-06-30 |
| NCT01634919 |
Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin |
https://ClinicalTrials.gov/show/NCT01634919 |
Completed |
Seoul National University Boramae Hospital |
2017-02-17 |
| NCT01609049 |
An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis |
https://ClinicalTrials.gov/show/NCT01609049 |
Completed |
Hoffmann-La Roche |
2015-06-22 |
| NCT01604291 |
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01604291 |
Completed |
Hoffmann-La Roche |
2016-02-10 |
| NCT01544582 |
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518) |
https://ClinicalTrials.gov/show/NCT01544582 |
Completed |
Merck Sharp & Dohme Corp. |
2015-07-31 |
| NCT01525810 |
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial |
https://ClinicalTrials.gov/show/NCT01525810 |
Completed |
Bristol-Myers Squibb |
2014-11-30 |
| NCT01514890 |
French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin |
https://ClinicalTrials.gov/show/NCT01514890 |
Completed |
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
2014-03-31 |
| NCT01508130 |
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 |
https://ClinicalTrials.gov/show/NCT01508130 |
Completed |
Hoffmann-La Roche |
2014-03-31 |
| NCT01492504 |
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial |
https://ClinicalTrials.gov/show/NCT01492504 |
Completed |
Bristol-Myers Squibb |
2018-03-16 |
| NCT01464008 |
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01464008 |
Completed |
Beijing Ditan Hospital |
2011-05-31 |
| NCT01457768 |
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response |
https://ClinicalTrials.gov/show/NCT01457768 |
Completed |
Gilead Sciences |
2018-04-09 |
| NCT01457755 |
Gilead Sustained Virologic Response (SVR) Registry |
https://ClinicalTrials.gov/show/NCT01457755 |
Completed |
Gilead Sciences |
2017-03-28 |
| NCT01453244 |
Pharmacogenomic Research in Korean Patients With Hepatitis C |
https://ClinicalTrials.gov/show/NCT01453244 |
Completed |
Inje University |
2013-03-31 |
| NCT01447446 |
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01447446 |
Completed |
Hoffmann-La Roche |
2015-07-31 |
| NCT01416610 |
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy |
https://ClinicalTrials.gov/show/NCT01416610 |
Completed |
Hoffmann-La Roche |
2014-10-31 |
| NCT01403181 |
Effect of Boceprevir on HCV-specific T Cell Responses |
https://ClinicalTrials.gov/show/NCT01403181 |
Completed |
Azienda Ospedaliero-Universitaria di Parma |
2013-10-31 |
| NCT01402583 |
Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT01402583 |
Completed |
University of Modena and Reggio Emilia |
2011-08-31 |
| NCT01392742 |
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin |
https://ClinicalTrials.gov/show/NCT01392742 |
Completed |
Hoffmann-La Roche |
2014-07-31 |
| NCT03348059 |
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy |
https://ClinicalTrials.gov/show/NCT03348059 |
Completed |
Hospices Civils de Lyon |
2016-11-30 |
| NCT01344889 |
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C) |
https://ClinicalTrials.gov/show/NCT01344889 |
Completed |
Hoffmann-La Roche |
2013-06-30 |
| NCT01342003 |
HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b |
https://ClinicalTrials.gov/show/NCT01342003 |
Completed |
Azienda Ospedaliera San Camillo Forlanini |
2010-07-31 |
| NCT01335230 |
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients |
https://ClinicalTrials.gov/show/NCT01335230 |
Completed |
University of Cincinnati |
2013-01-31 |
| NCT04352309 |
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis |
https://ClinicalTrials.gov/show/NCT04352309 |
Recruiting |
AbbVie |
2021-04-20 |
| NCT04330508 |
Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial |
https://ClinicalTrials.gov/show/NCT04330508 |
Recruiting |
Postgraduate Institute of Medical Education and Research |
2020-10-31 |
| NCT04214028 |
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus |
https://ClinicalTrials.gov/show/NCT04214028 |
Recruiting |
AbbVie |
2024-12-30 |
| NCT04189627 |
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation |
https://ClinicalTrials.gov/show/NCT04189627 |
Recruiting |
AbbVie |
2021-03-01 |
| NCT04094272 |
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection |
https://ClinicalTrials.gov/show/NCT04094272 |
Completed |
Kantonsspital Olten |
2019-05-01 |
| NCT04071353 |
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT04071353 |
Recruiting |
Beijing Ditan Hospital |
2020-08-01 |
| NCT03993925 |
Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong |
https://ClinicalTrials.gov/show/NCT03993925 |
Recruiting |
The University of Hong Kong |
2020-09-30 |
| NCT03880682 |
Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT03880682 |
Completed |
Istanbul University |
2019-06-15 |
| NCT03868163 |
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation |
https://ClinicalTrials.gov/show/NCT03868163 |
Active, not recruiting |
AbbVie |
2020-08-15 |
| NCT03346941 |
Side Effects After Direct-acting Antiviral Treatment |
https://ClinicalTrials.gov/show/NCT03346941 |
Completed |
Hospices Civils de Lyon |
2017-09-30 |
| NCT03740906 |
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting |
https://ClinicalTrials.gov/show/NCT03740906 |
Recruiting |
Kirby Institute |
2021-01-31 |
| NCT03740230 |
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs |
https://ClinicalTrials.gov/show/NCT03740230 |
Recruiting |
AbbVie |
2022-09-30 |
| NCT03693586 |
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis |
https://ClinicalTrials.gov/show/NCT03693586 |
Recruiting |
Hospital General de Mexico |
2020-05-01 |
| NCT03570112 |
Transmission of Chronic Hepatitis C in Pregnancy |
https://ClinicalTrials.gov/show/NCT03570112 |
Recruiting |
The Christ Hospital |
2020-06-30 |
| NCT03566563 |
Epidemiology of Chronic Hepatitis C and Disease Modelling |
https://ClinicalTrials.gov/show/NCT03566563 |
Recruiting |
Changi General Hospital |
2019-02-18 |
| NCT03551002 |
Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego |
https://ClinicalTrials.gov/show/NCT03551002 |
Recruiting |
University of California, San Diego |
2020-12-31 |
| NCT03520660 |
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents |
https://ClinicalTrials.gov/show/NCT03520660 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2032-12-31 |
| NCT03513796 |
Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside |
https://ClinicalTrials.gov/show/NCT03513796 |
Active, not recruiting |
NHS Tayside |
2018-12-31 |
| NCT03510637 |
“Real Life” Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt |
https://ClinicalTrials.gov/show/NCT03510637 |
Recruiting |
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
2020-08-31 |
| NCT03500562 |
Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) |
https://ClinicalTrials.gov/show/NCT03500562 |
Recruiting |
Bristol-Myers Squibb |
2021-12-31 |
| NCT03459768 |
Cohort Study on People Who Inject Drugs in Senegal |
https://ClinicalTrials.gov/show/NCT03459768 |
Active, not recruiting |
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
2020-02-29 |
| NCT03423641 |
An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C |
https://ClinicalTrials.gov/show/NCT03423641 |
Completed |
Kaiser Permanente |
2017-12-31 |
| NCT03413696 |
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients |
https://ClinicalTrials.gov/show/NCT03413696 |
Enrolling by invitation |
University of California, San Diego |
2019-12-31 |
| NCT01206933 |
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System |
https://ClinicalTrials.gov/show/NCT01206933 |
Completed |
George Washington University |
2015-06-30 |
| NCT01200225 |
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
https://ClinicalTrials.gov/show/NCT01200225 |
Completed |
Hoffmann-La Roche |
2013-06-30 |
| NCT01159613 |
Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection? |
https://ClinicalTrials.gov/show/NCT01159613 |
Completed |
Ziv Hospital |
2008-10-31 |
| NCT01112033 |
Biliverdin Reductase A in Chronic Hepatitis C Virus Infection |
https://ClinicalTrials.gov/show/NCT01112033 |
Completed |
Charles University, Czech Republic |
2013-03-31 |
| NCT01098097 |
Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) |
https://ClinicalTrials.gov/show/NCT01098097 |
Completed |
Merck Sharp & Dohme Corp. |
2011-10-31 |
| NCT01070550 |
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) |
https://ClinicalTrials.gov/show/NCT01070550 |
Completed |
Hoffmann-La Roche |
2011-07-31 |
| NCT01066819 |
PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b |
https://ClinicalTrials.gov/show/NCT01066819 |
Completed |
Hoffmann-La Roche |
2011-08-31 |
| NCT01066793 |
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b |
https://ClinicalTrials.gov/show/NCT01066793 |
Completed |
Hoffmann-La Roche |
2011-03-31 |
| NCT01054742 |
Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) |
https://ClinicalTrials.gov/show/NCT01054742 |
Completed |
Merck Sharp & Dohme Corp. |
2011-06-30 |
| NCT01033045 |
Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure |
https://ClinicalTrials.gov/show/NCT01033045 |
Completed |
Fundacion IMIM |
2013-07-31 |
| NCT00998621 |
ADHEPTA Study: Adherence Questionnaire in Hepatitis C |
https://ClinicalTrials.gov/show/NCT00998621 |
Completed |
Fundacion IMIM |
2010-09-30 |
| NCT00863109 |
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) |
https://ClinicalTrials.gov/show/NCT00863109 |
Completed |
Merck Sharp & Dohme Corp. |
2013-05-31 |
| NCT03000023 |
Anticipated and Perceived Benefits Following Hepatitis C Treatment |
https://ClinicalTrials.gov/show/NCT03000023 |
Completed |
University of North Carolina, Chapel Hill |
2018-07-31 |
| NCT03042520 |
Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment |
https://ClinicalTrials.gov/show/NCT03042520 |
Recruiting |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2022-09-30 |
| NCT03342261 |
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia |
https://ClinicalTrials.gov/show/NCT03342261 |
Completed |
Hospices Civils de Lyon |
2017-11-01 |
| NCT03246048 |
Long Term Follow-up of Hepatitis C Cured Patients |
https://ClinicalTrials.gov/show/NCT03246048 |
Active, not recruiting |
Hospital Universitari Vall d’Hebron Research Institute |
2021-01-31 |
| NCT02907996 |
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea |
https://ClinicalTrials.gov/show/NCT02907996 |
Recruiting |
Gilead Sciences |
2021-09-30 |
| NCT02581163 |
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium |
https://ClinicalTrials.gov/show/NCT02581163 |
Completed |
AbbVie |
2018-02-12 |
| NCT02578693 |
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) |
https://ClinicalTrials.gov/show/NCT02578693 |
Recruiting |
Humanity and Health Research Centre |
2020-12-31 |
| NCT02505243 |
Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens |
https://ClinicalTrials.gov/show/NCT02505243 |
Completed |
Radboud University |
2016-06-30 |
| NCT01280656 |
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION) |
https://ClinicalTrials.gov/show/NCT01280656 |
Completed |
Hoffmann-La Roche |
2012-11-30 |
| NCT01577069 |
Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir |
https://ClinicalTrials.gov/show/NCT01577069 |
Completed |
Association HGE CHU Bordeaux Sud |
2013-01-31 |
| NCT00770198 |
sgp130 in Chronic Human Liver Disease |
https://ClinicalTrials.gov/show/NCT00770198 |
Completed |
Erasme University Hospital |
2007-01-31 |
| NCT00736242 |
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) |
https://ClinicalTrials.gov/show/NCT00736242 |
Completed |
Merck Sharp & Dohme Corp. |
2011-12-31 |
| NCT00728494 |
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) |
https://ClinicalTrials.gov/show/NCT00728494 |
Completed |
Merck Sharp & Dohme Corp. |
2007-12-31 |
| NCT00727311 |
Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00727311 |
Completed |
Merck Sharp & Dohme Corp. |
2009-06-30 |
| NCT00726557 |
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) |
https://ClinicalTrials.gov/show/NCT00726557 |
Completed |
Merck Sharp & Dohme Corp. |
2009-01-31 |
| NCT00725751 |
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) |
https://ClinicalTrials.gov/show/NCT00725751 |
Completed |
Merck Sharp & Dohme Corp. |
2011-03-31 |
| NCT00725205 |
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) |
https://ClinicalTrials.gov/show/NCT00725205 |
Completed |
Merck Sharp & Dohme Corp. |
2010-10-31 |
| NCT00724893 |
Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) |
https://ClinicalTrials.gov/show/NCT00724893 |
Completed |
Merck Sharp & Dohme Corp. |
2012-08-31 |
| NCT00724854 |
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) |
https://ClinicalTrials.gov/show/NCT00724854 |
Completed |
Merck Sharp & Dohme Corp. |
2009-09-30 |
| NCT00724464 |
Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) |
https://ClinicalTrials.gov/show/NCT00724464 |
Completed |
Merck Sharp & Dohme Corp. |
2010-10-31 |
| NCT00724451 |
Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) |
https://ClinicalTrials.gov/show/NCT00724451 |
Completed |
Merck Sharp & Dohme Corp. |
2011-10-31 |
| NCT00724373 |
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00724373 |
Completed |
Merck Sharp & Dohme Corp. |
2009-02-28 |
| NCT00724295 |
Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) |
https://ClinicalTrials.gov/show/NCT00724295 |
Completed |
Merck Sharp & Dohme Corp. |
2008-12-31 |
| NCT00724230 |
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00724230 |
Completed |
Merck Sharp & Dohme Corp. |
2008-12-31 |
| NCT00723931 |
PegIntron Injection Surveillance Plan (Study P04123) |
https://ClinicalTrials.gov/show/NCT00723931 |
Completed |
Merck Sharp & Dohme Corp. |
2009-11-30 |
| NCT00723892 |
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) |
https://ClinicalTrials.gov/show/NCT00723892 |
Completed |
Merck Sharp & Dohme Corp. |
2009-05-31 |
| NCT00723645 |
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) |
https://ClinicalTrials.gov/show/NCT00723645 |
Completed |
Merck Sharp & Dohme Corp. |
2010-04-30 |
| NCT00723632 |
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00723632 |
Completed |
Merck Sharp & Dohme Corp. |
2010-12-31 |
| NCT00709228 |
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793) |
https://ClinicalTrials.gov/show/NCT00709228 |
Completed |
Merck Sharp & Dohme Corp. |
2008-11-30 |
| NCT00709059 |
Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) |
https://ClinicalTrials.gov/show/NCT00709059 |
Completed |
Merck Sharp & Dohme Corp. |
2009-12-31 |
| NCT00707603 |
Chronic Hepatitis C and Insulin Resistance |
https://ClinicalTrials.gov/show/NCT00707603 |
Completed |
Garvan Institute of Medical Research |
2008-12-31 |
| NCT00705666 |
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00705666 |
Completed |
Merck Sharp & Dohme Corp. |
2008-07-31 |
| NCT00705263 |
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00705263 |
Completed |
Schering-Plough |
2008-05-31 |
| NCT00705224 |
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) |
https://ClinicalTrials.gov/show/NCT00705224 |
Completed |
Merck Sharp & Dohme Corp. |
2010-08-31 |
| NCT00704964 |
Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) |
https://ClinicalTrials.gov/show/NCT00704964 |
Completed |
Merck Sharp & Dohme Corp. |
2009-10-31 |
| NCT00704717 |
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) |
https://ClinicalTrials.gov/show/NCT00704717 |
Completed |
Merck Sharp & Dohme Corp. |
2007-12-31 |
| NCT00704522 |
Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00704522 |
Completed |
Merck Sharp & Dohme Corp. |
2009-04-30 |
| NCT00700401 |
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). |
https://ClinicalTrials.gov/show/NCT00700401 |
Completed |
Hoffmann-La Roche |
2010-11-30 |
| NCT00659256 |
Hepatitis C Treatment and Atherosclerosis |
https://ClinicalTrials.gov/show/NCT00659256 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00610597 |
Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease |
https://ClinicalTrials.gov/show/NCT00610597 |
Completed |
Erasme University Hospital |
2007-01-31 |
| NCT00606528 |
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy |
https://ClinicalTrials.gov/show/NCT00606528 |
Completed |
University Health Network, Toronto |
2013-07-31 |
| NCT00473993 |
Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland |
https://ClinicalTrials.gov/show/NCT00473993 |
Completed |
Seidenberg, Arztpraxis A., M.D. |
NA |
| NCT00466336 |
Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices |
https://ClinicalTrials.gov/show/NCT00466336 |
Completed |
National Taiwan University Hospital |
2006-12-31 |
| NCT00466271 |
Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study |
https://ClinicalTrials.gov/show/NCT00466271 |
Completed |
National Taiwan University Hospital |
2008-11-30 |
| NCT00422838 |
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. |
https://ClinicalTrials.gov/show/NCT00422838 |
Completed |
Foundation for Liver Research |
2010-06-30 |
| NCT00361179 |
Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT00361179 |
Completed |
National Taiwan University Hospital |
NA |
| NCT00322179 |
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT00322179 |
Completed |
Palo Alto Veterans Institute for Research |
2007-11-30 |
| NCT00227149 |
Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT00227149 |
Completed |
University of Wuerzburg |
NA |
| NCT00216775 |
Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C |
https://ClinicalTrials.gov/show/NCT00216775 |
Completed |
Kyoto University |
2008-05-31 |
| NCT00187473 |
Natural History of Hepatitis C in Patients With Normal Liver Tests |
https://ClinicalTrials.gov/show/NCT00187473 |
Active, not recruiting |
University of California, San Francisco |
2020-12-31 |
| NCT00727259 |
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) |
https://ClinicalTrials.gov/show/NCT00727259 |
Completed |
Merck Sharp & Dohme Corp. |
2008-04-30 |